Introduction {#s1}
============

Several studies have demonstrated that there is an inverse association between cancer and dementia ([@B1]--[@B7]). An inverse association with cancer has also been found in other neurodegenerative diseases, such as Parkinson\'s disease ([@B8]--[@B10]). However, the underlying mechanisms are largely unknown. Previous studies suggested that dementia and many site-specific cancers share one or more common molecular mechanisms, such as signaling pathways and Pin enzyme ([@B11], [@B12]). Besides this, there are many other factors that might explain a link between cancer and dementia, including shared risk factors, age-related changes, and the possible effects of cancer treatment on the brain ([@B13]). Survival bias, which means that cancer survivors may be more likely to die before they can develop dementia, has been suggested to confound the observed association ([@B2], [@B14]). A potential mechanism is that biological pathway to cancer might be protective against dementia ([@B15]--[@B18]), but the existing evidence remains inconclusive. The observed inverse association is further complicated by the medical treatments of various types of cancer, which have been reported to be associated with either a higher or lower risk of dementia ([@B5], [@B19]--[@B21]).

In this population-based national study, we aimed to systematically explore the subsequent risk of dementia after the diagnosis of a total of 35 different cancers. The relative risk of dementia was stratified by follow-up time with a consideration of survival bias. We also explored the risk of dementia before the diagnosis of various cancers to control for the contribution by medical treatments of cancer. We further investigated the risk of dementia stratified by subtypes, i.e., Alzheimer\'s dementia (AD) or vascular dementia (VaD), which have a different underlying pathogenesis. AD is caused by neurodegenerative process whereas VaD is caused by cerebrovascular insults. This study, to the best of our knowledge, is the first nationwide large-scale study with more than 700,000 cancer cases included.

Methods {#s2}
=======

This retrospective cohort study was approved by the Ethics Committee at Lund University, Sweden. This study was carried out by combining data from the Swedish Cancer Register and the Swedish Hospital Discharge Register. The Swedish Cancer Register was founded in 1958 and has almost complete nationwide coverage ([@B22]). We identified all malignancies according to the 7th Revision of International Classification of Diseases (ICD-7 codes 140--209), as used in the Swedish Cancer Register ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The Swedish Hospital Discharge Register, which was founded in 1964, and has had complete nationwide coverage since 1987. All dementia patients were identified from the Swedish Hospital Discharge Register. In Sweden, dementia disorders are clinically diagnosed according to different versions of International Classification of Diseases, as used in the Swedish Hospital Discharge Register. Cognitive evaluation was performed using the mini-mental state examination (MMSE) scores ([@B23]). ICD-9 code of 290 was used to retrieve patients diagnosed with dementia in the years between 1987 and 1996. ICD-10 codes of F00-F03 and G30 were used for patients diagnosed between 1997 and 2015.

Study Population
----------------

The study population includes people who were born before 1947 and were still alive in 1992 (older than 45 at the beginning of the study). Using the Swedish Cancer Register, all people were identified who were diagnosed with cancer from January 1, 1992, to December 31, 2015. Only the first primary cancer was considered in the present study. At least three cancer-free individuals were matched with patients with cancer according to year and month of birth, gender, highest education level, country of origin, history of diabetes and hypertension. Individuals who had a diagnosis of any dementia before 1987 were excluded.

Covariates
----------

By linking to the Total Population Register and the Hospital Discharge Register, we could identify a range of demographic and clinical factors that might confound our results. The covariates included in the study were gender (male/female), age at diagnosis and time period at diagnosis of dementia, which were categorized into 5-year groups, highest education level, country of origin, diabetes (yes/no), and hypertension (yes/no). The highest education level was classified into four categories: (1) \<9 years, (2) 10--11 years, (3) \>12 years, and (4) unknown. Country of origin was grouped as being born in Sweden and born abroad ([@B24]).

Statistical Analysis
--------------------

Person-year at risk was calculated from the year and month of cancer diagnosis until the diagnosis of dementia, death, or the end of follow-up (December 31, 2015), whichever came first. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected number of cases. SIRs were used to measure the relative risk of dementia in individuals diagnosed with cancer compared with the matched cancer-free group. The expected number of cases was calculated based on age-, sex-, education-, country of origin-, period-, diabetes-, and hypertension-specific standard incidence rates derived from the matched cancer-free group. We excluded cancer types with \<10 dementia cases. We calculated 95% CIs assuming a Poisson distribution.

To determine if there were substantial differences in the association between cancer and dementia by type of cancer or dementia subtypes, we stratified the main analysis according to anatomical site (oral, salivary gland, esophageal, stomach, small intestine, colon, rectum, anus, liver, pancreas, nose, lung, breast, cervix, endometrium, uterus, ovary, other female genital, prostate, testis, other male genital, kidney, urinary bladder, melanoma, skin, eye, nervous system, thyroid gland, endocrine glands, bone, connective tissue, non-Hodgkin\'s lymphoma, Hodgkin\'s lymphoma, myeloma, and leukemia) and dementia classification (AD, VaD, and other dementia). Cancer cases were also classified into smoking-related cancers (oral, esophageal, stomach, pancreas, lung, cervix, kidney, and urinary bladder) and non-smoking-related cancers based on the evidence from IARC ([@B25]). To explore the possibility of survival bias, we calculated the risk of dementia stratified by follow-up interval (0--4, 5--9, and ≥10 years; [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). We investigated the incidence of dementia 5 years before the diagnosis of cancer to control for the confounding effects, such as negative surveillance bias and medication. We also assess the robustness of our research findings to unmeasured confounding by using the e-value as suggested by VanderWeele and Ding ([@B26]). All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

The demographic and clinical factors among patients with cancer and the matched controls are presented in [Table 1](#T1){ref-type="table"}. A total of 732,901 individuals diagnosed with cancer were retrieved from the databases. Male patients (55.3%) outnumbered female patients (44.7%). The median age at diagnosis of cancer was 73 years. After a mean of 5.46 years of follow-up, 14,090 (5.6‰) of the patients were diagnosed with dementia.

###### 

Basic demographic and clinical characteristics among patients with cancer and cancer-free controls.

  **Characteristics**     **Cancer group (*n* = 732901)**   **Cancer-free group (*n* = 1769357)**
  ----------------------- --------------------------------- ---------------------------------------
  **Gender**                                                
     Male                 405130 (55.3%)                    863382 (48.8%)
     Female               327771 (44.7%)                    905975 (51.2%)
  **Birth year**                                            
     \<1920               127770 (17.4%)                    352275 (19.9%)
     1920--1929           213316 (29.1%)                    450453 (25.5%)
     1930--1939           223622 (30.5%)                    496071 (28.0%)
     1940+                168193 (22.9%)                    470558 (26.6%)
     Median               1931                              1931
  **Birth country**                                         
     Sweden               663124 (90.5%)                    1571966 (88.8%)
     Others               69777 (9.5%)                      197391 (11.2%)
  **Education (years)**                                     
     1--9                 341364 (46.6%)                    815617 (46.1%)
     10--11               227412 (31.0%)                    530199 (30.0%)
     12+                  126581 (17.6%)                    294792 (16.7%)
     Unknown              37544 (5.1%)                      128749 (7.3%)
  **Diabetes**            114047 (15.6%)                    261130 (14.8%)
  **Hypertension**        289501 (39.5%)                    659407 (37.3%)

The overall risk of dementia was significantly lower among patients with cancer (SIR = 0.79, 95% CI 0.78--0.80) as compared to the controls after adjusting for a range of factors ([Table 2](#T2){ref-type="table"}). For specific cancer sites, the lowest risk of dementia was found after the diagnosis of pancreatic cancer (SIR = 0.30, 95% CI 0.18--0.47), followed by esophageal cancer (SIR = 0.34, 95% CI 0.19--0.56) and liver cancer (SIR = 0.39, 95% CI 0.27--0.54). A total of 21 cancer sites showed an inverse association with dementia. The inverse association was stronger for smoking-related cancers (SIR = 0.76, 95% CI 0.72--0.79) than for non-smoking-related cancers (SIR = 0.80, 95% CI 0.78--0.80). The e-values for the point estimate and upper confidence bound for dementia were shown in [Supplementary Table 2](#SM1){ref-type="supplementary-material"}.

###### 

Risk of dementia among patients with cancer stratified by anatomical site.

  **Cancer types**                                   **O**    **SIR[^\*^](#TN1){ref-type="table-fn"}(95% CI)**   
  -------------------------------------------------- -------- -------------------------------------------------- -----------------------
  Oral (upper aerodigestive tract)                   228      ![](fonc-10-00073-i0001.jpg)                       **0.76 (0.66--0.86)**
  Salivary gland                                     34       1.03 (0.71--1.43)                                  
  Esophageal                                         16       **0.34 (0.19--0.56)**                              
  Stomach                                            110      **0.59 (0.48--0.71)**                              
  Small intestine                                    46       **0.74 (0.54--0.99)**                              
  Colon                                              1,272    **0.81 (0.77--0.86)**                              
  Rectum                                             568      **0.71 (0.65--0.77)**                              
  Anus                                               29       0.75 (0.50--1.08)                                  
  Liver                                              34       **0.39 (0.27--0.54)**                              
  Pancreas                                           18       **0.30 (0.18--0.47)**                              
  Nose                                               21       1.05 (0.65--1.61)                                  
  Lung                                               260      **0.65 (0.57--0.73)**                              
  Breast                                             2,124    **0.86 (0.82--0.90)**                              
  Cervix                                             65       0.85 (0.65--1.08)                                  
  Endometrium                                        558      **0.80 (0.73--0.86)**                              
  Ovary                                              113      **0.60 (0.49--0.72)**                              
  Other female genitals                              60       0.82 (0.62--1.05)                                  
  Prostate                                           3,724    **0.76 (0.73**--**0.78)**                          
  Testis                                             12       1.22 (0.63--2.14)                                  
  Other male genitals                                26       0.73 (0.48--1.07)                                  
  Kidney                                             251      **0.73 (0.64**--**0.83)**                          
  Urinary bladder                                    972      **0.87 (0.81**--**0.92)**                          
  Melanoma                                           538      **0.72 (0.66**--**0.78)**                          
  Skin                                               1,478    **0.87 (0.83**--**0.92)**                          
  Eye                                                30       0.70 (0.47--1.00)                                  
  Nervous system                                     228      0.98 (0.86--1.11)                                  
  Thyroid gland                                      54       **0.76 (0.57**--**0.99)**                          
  Endocrine glands                                   319      1.03 (0.92--1.15)                                  
  Connective tissue                                  65       0.81 (0.63--1.04)                                  
  Non-Hodgkin\'s lymphoma                            538      **0.75 (0.69**--**0.82)**                          
  Hodgkin\'s disease                                 16       0.72 (0.41--1.17)                                  
  Myeloma                                            124      **0.78 (0.64**--**0.92)**                          
  Leukemia                                           159      **0.80 (0.68**--**0.94)**                          
  Smoking-related[^\#^](#TN2){ref-type="table-fn"}   1920     **0.76 (0.72**--**0.79)**                          
  Non-smoking-related                                12,170   **0.80 (0.78**--**0.81)**                          
  All                                                14,090   **0.79 (0.78**--**0.80)**                          

*Adjusted for age, sex, education, birth country, period of dementia diagnosis, diabetes, and hypertension*.

*Defined as cancer of the oral, esophageal, stomach, pancreas, lung, cervix, kidney, and urinary bladder*.

*Bold values indicate SIR less than 1 and 95% CI does include 1.00*.

The risk of dementia was further stratified by follow-up interval as shown in [Table 3](#T3){ref-type="table"}. Within 5 years before the diagnosis of cancer, the overall risk of dementia was 0.86 (95% CI 0.83--0.89). It was 0.60 (95% CI 0.58--0.61) during the first 5 years after the diagnosis of cancer, and 0.91 (95% CI 0.88--0.94) during the follow-up interval of 5--9 years. However, the overall risk of dementia was higher for cancer survivors who survived more than 10 years (SIR = 1.37, 95% CI 1.32--1.41). The lower risk was more evident in smoking-related cancer than in non-smoking-related cancer (SIR = 0.81 vs. 0.88, respectively) for patients who were diagnosed with dementia before the diagnosis of cancer. For specific cancer, we didn\'t find a lower risk of dementia during the whole follow-up period. For patients, who had survived for more than 5 years, only patients with rectal cancer (SIR = 0.85, 95% CI 0.69--0.97), breast cancer (SIR = 0.86, 95% CI 0.79--0.93), prostate cancer (SIR = 0.94, 95% CI 0.89--0.99), melanoma (SIR = 0.71, 95% CI 0.60--0.84), and non-Hodgkin\'s lymphoma (SIR = 0.82, 95% CI 0.69--0.97) showed a lower risk of dementia.

###### 

Risk of dementia among patients with cancer stratified by different follow up period.

  **Cancer types**                                   **Before the diagnosis**   **After the diagnosis**                                                                                            
  -------------------------------------------------- -------------------------- ------------------------- ------------ ------ ---------- ------------ ------ ---------- ------------ ------ ------ ------------
  Oral (upper aerodigestive tract)                   87                         1.04                      0.84--1.29   100    **0.55**   0.45--0.67   70     0.92       0.72--1.16   58     1.29   0.98--1.67
  Salivary gland                                     7                          0.78                      0.31--1.62   13     0.69       0.37--1.19   11     1.26       0.62--2.26   10     1.77   0.84--3.24
  Esophageal                                         56                         1.17                      0.88--1.52   12     **0.33**   0.17--0.57   2      0.31       0.03--1.15   2      0.55   0.05--2.04
  Stomach                                            118                        0.87                      0.72--1.04   61     **0.47**   0.36--0.61   27     0.74       0.49--1.07   22     1.05   0.66--1.59
  Small intestine                                    13                         0.58                      0.31--1.00   20     **0.51**   0.31--0.80   11     0.73       0.36--1.31   15     1.91   1.07--3.16
  Colon                                              407                        **0.81**                  0.73--0.89   568    **0.60**   0.55--0.65   394    1.00       0.90--1.10   310    1.43   1.27--1.59
  Rectum                                             188                        **0.83**                  0.70--0.96   259    **0.54**   0.48--0.61   170    **0.85**   0.72--0.98   139    1.17   0.98--1.38
  Anus                                               19                         1.56                      0.94--2.44   11     **0.48**   0.24--0.85   10     1.04       0.50--1.93   8      1.33   1.57--2.64
  Liver                                              102                        **0.81**                  0.66--0.99   17     **0.24**   0.14--0.38   10     0.95       0.45--1.75   7      1.15   0.46--2.38
  Pancreas                                           107                        0.87                      0.71--1.05   16     **0.29**   0.17--0.48   2      0.57       0.05--2.09   0      \-     \-
  Nose                                               7                          1.08                      0.43--2.24   8      0.64       0.27--1.26   6      1.15       0.41--2.51   7      3.20   1.27--6.62
  Lung                                               239                        **0.69**                  0.61--0.78   154    **0.48**   0.41--0.57   64     1.12       0.86--1.43   42     1.56   1.12--2.11
  Breast                                             598                        1.17                      1.08--1.27   788    **0.63**   0.59--0.68   580    **0.86**   0.79--0.93   756    1.39   1.29--1.49
  Cervix                                             35                         1.35                      0.94--1.88   24     **0.59**   0.38--0.88   19     1.02       0.61--1.60   22     1.27   0.79--1.92
  Endometrium                                        151                        1.15                      0.97--1.35   180    **0.54**   0.46--0.62   173    0.87       0.75--1.01   205    1.22   1.06--1.40
  Ovary                                              44                         **0.72**                  0.52--0.97   33     **0.30**   0.20--0.42   36     0.87       0.61--1.21   44     1.21   0.88--1.63
  Other female genitals                              30                         0.87                      0.58--1.24   34     0.75       0.52--1.05   14     0.80       0.43--1.34   12     1.14   0.58--1.99
  Prostate                                           569                        **0.62**                  0.57--0.67   1669   **0.55**   0.53--0.58   1293   **0.94**   0.89--0.99   762    1.42   1.32--1.53
  Testis                                             3                          2.86                      0.54--8.48   3      0.75       0.14--2.23   5      2.00       0.63--4.71   4      1.20   0.31--3.09
  Other male genitals                                14                         1.56                      0.85--2.63   18     0.85       0.50--1.34   4      0.42       0.11--1.08   4      0.85   0.22--2.20
  Kidney                                             44                         **0.47**                  0.34--0.63   105    **0.53**   0.43--0.64   80     0.90       0.72--1.12   66     1.20   0.93--1.52
  Urinary bladder                                    251                        **0.83**                  0.73--0.93   436    **0.66**   0.60--0.72   286    0.98       0.87--1.10   250    1.50   1.32--1.70
  Melanoma                                           197                        1.16                      1.00--1.33   223    **0.53**   0.46--0.61   141    **0.71**   0.60--0.84   174    1.28   1.10--1.49
  Skin                                               627                        1.07                      0.99--1.16   839    **0.77**   0.72--0.83   388    0.92       0.83--1.02   251    1.33   1.17--1.50
  Eye                                                6                          0.68                      0.24--1.48   7      **0.28**   0.11--0.58   9      0.80       0.36--1.53   14     2.07   1.13--3.48
  Nervous system                                     77                         1.27                      1.00--1.59   89     **0.79**   0.64--0.98   61     0.95       0.73--1.22   78     1.38   1.09--1.72
  Thyroid gland                                      9                          **0.48**                  0.22--0.91   14     **0.39**   0.21--0.65   21     1.11       0.68--1.70   19     1.18   0.71--1.84
  Endocrine glands                                   50                         1.29                      0.95--1.70   129    0.93       0.78--1.10   93     1.03       0.83--1.27   97     1.20   0.97--1.46
  Connective tissue                                  25                         0.96                      0.62--1.42   31     **0.65**   0.44--0.93   20     1.00       0.61--1.55   14     1.13   0.62--1.90
  Non-Hodgkin\'s lymphoma                            155                        **0.67**                  0.57--0.79   260    **0.57**   0.51--0.65   145    **0.82**   0.69--0.97   133    1.59   1.33--1.88
  Hodgkin\'s disease                                 3                          0.44                      0.08--1.31   5      **0.40**   0.13--0.94   6      1.05       0.38--2.30   5      1.23   0.39--2.90
  Myeloma                                            49                         **0.66**                  0.49--0.87   92     **0.71**   0.57--0.87   16     0.69       0.40--1.13   16     2.34   1.33--3.81
  Leukemia                                           60                         **0.58**                  0.44--0.75   95     **0.69**   0.56--0.85   40     0.93       0.66--1.27   24     1.34   0.86--1.99
  Smoking related[^\#^](#TN4){ref-type="table-fn"}   937                        **0.81**                  0.76--0.86   908    **0.56**   0.52--0.60   550    0.95       0.87--1.03   462    1.37   1.25--1.50
  Non-smoking related                                3410                       **0.88**                  0.85--0.90   5405   **0.60**   0.59--0.62   3657   **0.91**   0.88--0.94   3108   1.37   1.31--1.41
  All                                                4347                       **0.86**                  0.83--0.89   6313   **0.60**   0.58--0.61   4207   **0.91**   0.88--0.94   3570   1.37   1.32--1.41

*Adjusted for age, sex, education, birth country, period of dementia diagnosis, diabetes, and hypertension*.

*Defined as cancer of the oral, esophageal, stomach, pancreas, lung, cervix, kidney, and urinary bladder*.

*Bold values indicate SIR less than 1 and 95% CI does include 1.00*.

The risks of dementia by subtypes are presented in [Table 4](#T4){ref-type="table"}. The overall risk of AD was 0.82 (95% CI 0.80--0.85), 0.78 (95% CI 0.75--0.80) for VaD, and 0.78 (95% CI 0.76--0.80) for other dementia types. The lower risk was more evident in smoking-related cancer than in non-smoking-related cancer (SIR = 0.77 vs. 0.84, respectively) for patients who were diagnosed with AD. For specific cancer site, a total of 12 cancer sites showed an inverse association with all the three dementia subtypes.

###### 

Risk of dementia among patients with cancer stratified by different kinds of dementia.

  **Cancer types**                                   **Alzheimer\'s**   **Vascular dementia**   **Other dementia**                                                    
  -------------------------------------------------- ------------------ ----------------------- -------------------- ------ ---------- ------------ ------ ---------- ------------
  Oral (upper aerodigestive tract)                   78                 0.87                    0.69--1.08           65     **0.70**   0.54--0.89   85     **0.73**   0.58--0.90
  Salivary gland                                     18                 1.76                    1.04--2.79           5      0.50       0.16--1.18   11     0.85       0.42--1.52
  Esophageal                                         3                  **0.22**                0.04--0.64           4      **0.28**   0.07--0.71   9      **0.49**   0.22--0.93
  Stomach                                            31                 **0.58**                0.40--0.93           34     **0.59**   0.41--0.82   45     **0.61**   0.44--0.81
  Small intestine                                    11                 0.56                    0.28--1.01           13     0.69       0.37--1.18   22     0.94       0.59--1.42
  Colon                                              425                **0.90**                0.81--0.98           348    **0.74**   0.67--0.83   499    **0.80**   0.73--0.87
  Rectum                                             185                **0.78**                0.67--0.90           160    0.65       0.56--0.76   223    **0.71**   0.62--0.81
  Anus                                               8                  0.63                    0.27--1.24           7      0.66       0.29--1.37   14     0.98       0.54--1.61
  Liver                                              9                  **0.33**                0.15--0.63           9      **0.34**   0.15--0.64   16     **0.47**   0.27--0.77
  Pancreas                                           1                  0.05                    0.00--0.30           4      **0.22**   0.06--0.58   13     **0.57**   0.30--0.98
  Nose                                               5                  0.82                    0.26--1.92           10     1.70       0.81--3.14   6      0.75       0.27--1.64
  Lung                                               90                 **0.69**                0.56--0.85           65     **0.55**   0.42--0.70   105    **0.68**   0.56--0.83
  Breast                                             824                **0.91**                0.85--0.97           527    **0.86**   0.79--0.94   773    **0.82**   0.76--0.88
  Cervix                                             20                 0.74                    0.46--1.15           13     0.70       0.35--1.15   32     1.05       0.72--1.49
  Endometrium                                        205                **0.83**                0.72--0.95           144    **0.78**   0.66--0.92   209    **0.78**   0.68--0.90
  Ovary                                              54                 0.80                    0.60--1.04           22     **0.46**   0.29--0.70   37     **0.50**   0.35--0.69
  Other female genitals                              19                 0.82                    0.49--1.28           14     0.73       0.40--1.22   27     0.87       0.57--1.27
  Prostate                                           1127               **0.80**                0.75--0.85           1262   **0.77**   0.73--0.82   1335   **0.72**   0.68--0.76
  Testis                                             2                  0.66                    0.06--2.44           4      1.21       0.31--3.13   6      1.71       0.62--3.75
  Other male genitals                                10                 1.03                    0.49--1.91           7      0.58       0.23--1.21   9      0.65       0.29--1.24
  Kidney                                             83                 **0.78**                0.62--0.97           82     **0.76**   0.60--0.94   86     **0.69**   0.55--0.84
  Urinary bladder                                    282                **0.87**                0.77--0.98           325    0.89       0.80--1.00   365    **0.85**   0.76--0.94
  Melanoma                                           175                **0.70**                0.60--0.81           158    **0.72**   0.61--0.84   205    **0.74**   0.64--0.85
  Skin                                               448                **0.89**                0.81--0.98           448    **0.90**   0.82--0.98   582    **0.84**   0.78--0.92
  Eye                                                11                 0.80                    0.40--1.43           7      0.55       0.22--1.14   12     0.72       0.37--1.27
  Nervous system                                     59                 **0.73**                0.55--0.94           51     0.77       0.57--1.02   118    1.39       1.15--1.66
  Thyroid gland                                      16                 0.66                    0.38--1.07           16     0.79       0.45--1.29   22     0.82       0.51--1.24
  Endocrine glands                                   102                1.00                    0.82--1.22           94     1.03       0.83--1.26   123    1.07       0.89--1.27
  Connective tissue                                  16                 0.66                    0.38--1.07           22     0.92       0.57--1.39   27     0.85       0.56--1.24
  Non-Hodgkin\'s lymphoma                            164                **0.73**                0.62--0.85           147    **0.70**   0.59--0.83   227    **0.82**   0.72--0.93
  Hodgkin\'s disease                                 5                  0.69                    0.22--1.63           6      0.88       0.32--1.93   5      0.61       0.19--1.42
  Myeloma                                            37                 0.76                    0.54--1.05           34     **0.71**   0.49--0.99   53     0.84       0.63--1.09
  Leukemia                                           52                 0.82                    0.61--1.08           50     0.87       0.64--1.15   57     **0.76**   0.58--0.99
  Smoking related[^\#^](#TN6){ref-type="table-fn"}   588                **0.77**                0.71--0.84           592    **0.75**   0.69--0.81   740    **0.76**   0.71--0.82
  Non-smoking related                                3987               **0.84**                0.81--0.86           3565   **0.78**   0.76--0.81   4618   **0.78**   0.76--0.81
  All                                                4575               **0.82**                0.80--0.85           4157   **0.78**   0.75--0.80   5358   **0.78**   0.76--0.80

*Adjusted for age, sex, education, birth country, period of dementia diagnosis, diabetes, and hypertension*.

*Defined as cancer of the oral, esophageal, stomach, pancreas, lung, cervix, kidney, and urinary bladder*.

*Bold values indicate SIR less than 1 and 95% CI does include 1.00*.

Discussion {#s4}
==========

In this population-based nationwide cohort study, we found that the incidence of dementia was significantly lower among patients with cancer as compared to the matched cancer-free group. The overall risk of dementia continued to be significantly lower until 10 years of follow-up, suggesting that the lower risk of dementia may only partially lie behind survival bias. Furthermore, the decrease in dementia risk was also significantly before the diagnosis of cancer, which suggests that the observed inverse association might represent a "true" finding, rather than simply an artifact of survival bias or under-diagnosis.

The inverse relation between cancer and dementia was found in a total of 21 cancer sites in our study. Our finding shows that the inverse relation was more evident in smoking-related cancers than non-smoking-related cancers for patients who were diagnosed with AD, which was consistent with previous report ([@B2]), but similar in other subtypes of dementia. Smoking is a well-known risk factor for both dementia and a few types of cancer ([@B27]); we thus can speculate that the observed inverse association between cancer and dementia cannot entirely be explained by smoking-related factors. Other vascular-related factors, such as hypertension and diabetes ([@B28]), were also included in the analytical model; thus, these factors may play a minor role in the observed association. In addition, the observed inverse associations were noted in all dementia subtypes, including AD, VaD, and other dementias; thus, the contribution by vascular-related factors can be further excluded. When we stratified the risk of dementia by follow-up interval, the inverse association was observed until 10 years of follow-up. In addition, the risk of dementia was also lower before the diagnosis of cancer, suggesting that survival bias and medical treatments of cancer cannot explain the observed negative association.

Our data suggested that the observed inverse association between dementia and cancer might be a true finding, but the underlying mechanisms are still largely unknown ([@B15]). Differential regulation of common genes and pathways might be related to the inverse association between cancer and dementia. Abnormal cell behaviors are the essence of both cancer and dementia ([@B29]). Cancer is characterized by unlimited cellular proliferation, whereas dementia is a process of premature cell death. Previous studies have shown that cancer and dementia may have shared genes and biological pathways, but these are often regulated in different directions ([@B11], [@B30]). A genome-wide association study found significant genetic associations between cancer and dementia, and some gene expression regulators have opposite regulatory effects on cancer and dementia ([@B15]). Previous studies have also found overlapping genes and signaling pathways between cancer and dementia ([@B12]). Pin1 enzyme plays a critical but opposite role in cancer and dementia ([@B31]--[@B34]). Over-expression of Pin1 can promote tumorigenesis as shown in cancers of the prostate, lung, breast, and so on ([@B33]). However, the overexpression of Pin1 gene in nerve cell has a neuroprotective effect by restoring phosphorylated tau and amyloid precursor protein to a functional state ([@B31]). Another gene that is regulated differentially in cancer and dementia is tumor suppressor protein P53, which is usually expressed less in patients with cancer but overexpressed in patients with dementia ([@B35]).

Medical treatment of cancer might confound the association between cancer and dementia. In our study, patients who survived more than 10 years had a higher risk of dementia as compared to the matched controls thus suggesting that medical treatment of cancer could influence the development of dementia. This may due to that chemotherapy can impair cognitive function, and patients with chemotherapy can have short-term or long-term changes in brain structure and function ([@B13]). Animal studies have indicated that some drugs might have neuroprotective effects ([@B21], [@B36]). A study on patients with breast cancer using the Surveillance, Epidemiology and End Results (SEER)-Medicare database showed no significant association between chemotherapy and cognitive impairment, but the incidence of AD and VaD was reduced ([@B20]). Another study that used the same database showed a possibility of severe cognitive changes associated with chemotherapy, particularly over a longer follow-up ([@B13]). Based on the evidence above, we can speculate that the effect of chemotherapy on the development of dementia might be complicated, which might depend on the doses and the types of different chemotherapeutical drugs. Unfortunately, information about medical treatment for cancer is not available in our databases, which calls for further studies using extended databases to explore their contributions. In addition, the explanation for the higher risk of dementia for cancer survivors after following up for more than 10 years might be due to aging-related cognitive decline, as well as continuous stress during the long-standing survival.

There are some strengths and limitations of this population-based study. A key strength of our study is that this is the first nationwide large-scale study to investigate the association between cancer and dementia by linking several nationwide Swedish registers. All the patients with cancer and patients with dementia were identified from the nationwide databases with high accuracy and high coverage ([@B37]). Using the data of nationwide registers can guarantee the completeness of the follow-up. A limitation of this study is that we lack information of other individual-related factors, such as polymorphisms association with dementia, smoking and physical activity. However, the e-value indicated that the observed SIR of 0.79 for overall dementia could only be explained by an unmeasured confounder that was associated with both cancer and dementia by a risk ratio of more than 1.85. Given that this risk ratio is greater than any observed for known dementia risk factors examined in the previous study, such as hypertension, diabetes, or smoking ([@B38]), it is implausible that an unmeasured confounder might explain the observed findings.

In conclusion, this population-based national cohort study suggested that the inverse association between cancer and dementia could not be due to survival bias or under-diagnosis. Further studies are needed to explore the underlying mechanisms.
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